Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Comment by carduon Nov 07, 2010 1:21pm

283 Views

Post# 17670519

RE: Weekly Assessment - The Cheshire Cat Told Me

"Who in their right mind would short Oncolytics going into the Fall research conference season unless they had insider information?"

I agree 100%. Though I don't expect anything will be done about it! This is Canada , not the US.

What will be interesting to me is if the stock keeps rising, even incrementally, Mr. Thomson is going to look quite incompetant by selling the shares at $4.60, or was it a quid pro quo to a potential partner?

Bullboard Posts

Thunder Gold makes generational discovery